[go: up one dir, main page]

CO5251477A1 - Compuestos farmaceuticamente activos - Google Patents

Compuestos farmaceuticamente activos

Info

Publication number
CO5251477A1
CO5251477A1 CO00077467A CO00077467A CO5251477A1 CO 5251477 A1 CO5251477 A1 CO 5251477A1 CO 00077467 A CO00077467 A CO 00077467A CO 00077467 A CO00077467 A CO 00077467A CO 5251477 A1 CO5251477 A1 CO 5251477A1
Authority
CO
Colombia
Prior art keywords
alkyl
alkenyl
cycloalkyl
haloalkyl
alkoxy
Prior art date
Application number
CO00077467A
Other languages
English (en)
Inventor
Mark Edward Bunnage
Keith Michael Devries
James Harris Laurence
Philip Charles Levett
John Paul Mathias
Joanna Teresa Negri
Street Stephen Derek Albert
Albert Shaw Wodd
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26244757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5251477(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9924063.2A external-priority patent/GB9924063D0/en
Priority claimed from GB0018656A external-priority patent/GB0018656D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of CO5251477A1 publication Critical patent/CO5251477A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • C07D213/80Acids; Esters in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un compuesto de fórmula (I): <EMI FILE="00077467_1" ID="1" IMF=JPEG >una sal farmacéutica o veterinariamente aceptable, o un solvato o farmacéutica o veterinariamente aceptable del mismo, en la que R1 es alquilo C1 a C6 o alquenilo C3 a C6, cicloalquilo C3 a C6, o ciclo alquenilo C4 a C6, pudiendo ser dicho grupo alquilo de cadena lineal o ramifícada, y en la que cuando R1 es alquilo C4 a C6, alquenilo C3 a C6, o cicloalquilo C3 a C6, dicho grupo alquilo, alquenilo o cicloalquilo esta opcionalmente sustituidos con; uno o más sustituyentes seleccionados entre: hidroxi; alcoxi C1 a C4; cicloalquilo C3 a C6; fenilo sustituido con uno o más sustituyentes seleccionados entre alquilo C1 a C3, alcoxi C1 a C4, haloalquilo C1 a C4, haloalcoxi C1 a C4, halo, CN, NO2, NHR11, NHCOR12, NHSO2R12, SO2R12, SO2NHR11, COR11 o CO2R11, conteniendo dichos grupos haloalquilo y haloalcoxi uno o más átomos de halo; NR7R8, CONR7R8 o NR7COR11, en los que cada uno de R7 y R8 se selecciona independientemente entre H, alquilo C1 a C4, alquenilo C3 a C4, CO2R9 o SO2R9, estando dichos grupos alquilo o alquenilo opcionalmente sustituidos con haloalquilo C1 a C4 o haloalcoxi C1 a C4; Het1; Het2 o Het3;O R1 es Het4 o fenilo, estando dicho grupo fenilo opcionalmente sustituido con uno o más sustituyentes seleccionados entre alquilo C1 a C4, alquenilo C3 a C4, alcoxi C1 a C4 halo, CN, CF3, OCF3, NO2, NHR11, NHCOR12, NHSO2 R12, SO2 R12, SO2NHR11 , COR11 y CO2R11; R2 es alquillo C1 a C6, alquenilo C3 a C6 o (CH2)n(cicloalquilo C3 a C6) , siendo n 0, 1 ó 2; ...
CO00077467A 1999-10-11 2000-10-11 Compuestos farmaceuticamente activos CO5251477A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9924063.2A GB9924063D0 (en) 1999-10-11 1999-10-11 Pharmaceutically active compounds
GB0018656A GB0018656D0 (en) 2000-07-28 2000-07-28 Pharmaceutically active compounds

Publications (1)

Publication Number Publication Date
CO5251477A1 true CO5251477A1 (es) 2003-02-28

Family

ID=26244757

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00077467A CO5251477A1 (es) 1999-10-11 2000-10-11 Compuestos farmaceuticamente activos

Country Status (49)

Country Link
US (4) US6677335B1 (es)
EP (1) EP1220856B1 (es)
JP (1) JP3834236B2 (es)
KR (1) KR100549152B1 (es)
CN (3) CN1204138C (es)
AP (1) AP1238A (es)
AT (1) ATE284404T1 (es)
AU (1) AU779065B2 (es)
BG (1) BG106678A (es)
BR (1) BR0014698A (es)
CA (1) CA2387357C (es)
CO (1) CO5251477A1 (es)
CR (2) CR6617A (es)
CU (1) CU23198A3 (es)
CZ (1) CZ20021158A3 (es)
DE (1) DE60016615T2 (es)
DK (1) DK1220856T3 (es)
DZ (1) DZ3220A1 (es)
EA (1) EA004982B1 (es)
EE (1) EE05181B1 (es)
EG (1) EG24411A (es)
ES (1) ES2232502T3 (es)
GE (2) GEP20033068B (es)
GT (1) GT200000171A (es)
HK (3) HK1050367A1 (es)
HR (1) HRP20020317B1 (es)
HU (1) HUP0203450A3 (es)
IL (2) IL149026A0 (es)
IN (4) IN2002MU00385A (es)
IS (1) IS2181B (es)
MA (1) MA26825A1 (es)
MX (1) MX228340B (es)
MY (1) MY130319A (es)
NO (1) NO322856B1 (es)
NZ (1) NZ518078A (es)
OA (1) OA12061A (es)
PA (1) PA8504501A1 (es)
PE (1) PE20010737A1 (es)
PH (1) PH12000002783B1 (es)
PL (1) PL357536A1 (es)
PT (1) PT1220856E (es)
RS (1) RS50476B (es)
SI (1) SI1220856T1 (es)
SK (1) SK4602002A3 (es)
SV (1) SV2002000195A (es)
TN (1) TNSN00199A1 (es)
TR (1) TR200200989T2 (es)
TW (1) TWI265925B (es)
WO (1) WO2001027113A2 (es)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
GB0000561D0 (en) * 2000-01-11 2000-03-01 Pfizer Ltd Treatment of diabetic ulcers
CA2406947A1 (en) * 2000-04-19 2001-10-25 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
US6271228B1 (en) * 2000-04-28 2001-08-07 Pfizer Inc. Blood pressure stabilization during hemodialysis
US6420557B1 (en) 2000-07-28 2002-07-16 Pfizer Inc. Crystalline therapeutic agent
US6407259B1 (en) 2000-07-28 2002-06-18 Pfizer Inc. Process for the preparation of pyrazoles
EP1176142A1 (en) * 2000-07-28 2002-01-30 Pfizer Inc. Process for the preparation of pyrazoles
YU4703A (sh) * 2000-07-28 2006-01-16 Pfizer Inc. Kristalni terapeutski agens
GB0025782D0 (en) * 2000-10-20 2000-12-06 Pfizer Ltd Use of inhibitors
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
FR2820319B3 (fr) * 2001-02-08 2003-12-05 Ellipse Pharmaceuticals Procede de fabrication d'un comprime flottant incluant de l'alfuzosine et comprime obtenu
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
KR20050004195A (ko) * 2002-05-23 2005-01-12 화이자 인코포레이티드 신규 조합 제제
GB0214784D0 (en) * 2002-06-26 2002-08-07 Pfizer Ltd Novel combination
DE10229778A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Neue Verwendung von Imidazotriazinonen
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
SI1572173T1 (sl) 2002-12-13 2010-08-31 Warner Lambert Co Alfa-2-delta ligand za zdravljenje simptomov spodnjega dela sečil
PE20050521A1 (es) 2003-02-27 2005-09-11 Uriach Y Compania S A J Derivados de pirazolopiridina
AU2004234158B2 (en) 2003-04-29 2010-01-28 Pfizer Inc. 5,7-diaminopyrazolo[4,3-D]pyrimidines useful in the treatment of hypertension
WO2004108138A1 (en) * 2003-06-10 2004-12-16 Pfizer Limited Therapeutic combinations comprising pde inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhoea
JP2006219373A (ja) * 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pde7阻害作用を有するピリジニルピラゾロピリミジノン誘導体
US7291640B2 (en) 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
DE10360835A1 (de) * 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
JP2007532526A (ja) 2004-04-07 2007-11-15 ファイザー・インク ピラゾロ[4,3−d]ピリミジン類
EP1863795B1 (en) 2005-03-21 2008-10-29 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
PL1881985T3 (pl) 2005-05-12 2011-05-31 Pfizer Bezwodne krystaliczne postacie N-[1-(2-etoksyetylo)-5-(N-etylo-N-metyloamino)-7-(4-metylopirydyn-2-yloamino)-1H-pirazolo[4,3-d]pirymidyno-3-karbonylo]metano-sulfonoamidu
WO2006133261A2 (en) 2005-06-06 2006-12-14 Intra-Cellular Therapies, Inc. Organic compounds
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス,インコーポレイティド Pde阻害による神経新生の調節
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
TW200733975A (en) * 2005-12-20 2007-09-16 Pfizer Prod Inc Pharmaceutical combination for the treatment of luts
JP2009520806A (ja) * 2005-12-21 2009-05-28 ファイザー・プロダクツ・インク PDE−5阻害薬と5−α還元酵素阻害薬の医薬組合せ
UY30111A1 (es) * 2006-02-03 2007-04-30 Recordati Ireland Ltd Sales de adicion de acido de n-(3-(4-(2-metoxifenil)-1-piperazinil)-propil)-7-oxo-5-trifluormetil-7h-tieno (3,2-b) piran-3-carboxamida
US20070244143A1 (en) * 2006-03-08 2007-10-18 Braincells, Inc Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
MX2008015489A (es) 2006-06-06 2009-01-13 Intra Cellular Therapies Inc Compuestos organicos.
US20080051413A1 (en) * 2006-08-25 2008-02-28 Kaohsiung Medical University Nitrophenylpiperazine derivative of xanthine which relaxes tracheal airway and increases respiratory performance
MX2009002496A (es) * 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
EP2066355A2 (en) * 2006-09-19 2009-06-10 Braincells, Inc. Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080081816A1 (en) * 2006-10-03 2008-04-03 Kaohsiung Medical University Anti-inflammation activity of newly synthesized xanthine derivatives kmup-1 and kmup-3
EP2089034A4 (en) 2006-12-05 2010-07-28 Intra Cellular Therapies Inc NEW USES
MX2010006208A (es) 2007-12-06 2010-12-21 Intra Cellular Therapies Inc Compuestos organicos.
US8697710B2 (en) 2008-12-06 2014-04-15 Intra-Cellular Therapies, Inc. Optionally substituted 3-amino-4-(thioxo or imino)-4,5-dihydro-2H-pyrazolo [3,4-d]pyrimidin-6(7H)-ones
AU2009322903A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
EP2367428B1 (en) 2008-12-06 2016-04-06 Intra-Cellular Therapies, Inc. Organic compounds
MX2011005933A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
MA32941B1 (fr) 2008-12-06 2012-01-02 Intra Cellular Therapies Inc Composes organiques
MA32937B1 (fr) 2008-12-06 2012-01-02 Intra Cellular Therapies Inc Composes organiques
JP2012513464A (ja) 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ホスホジエステラーゼ阻害剤及びその使用
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
EP2576551A4 (en) 2010-05-31 2014-04-16 Intra Cellular Therapies Inc ORGANIC COMPOUNDS
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
EP2590657A4 (en) 2010-05-31 2014-02-12 Intra Cellular Therapies Inc ORGANIC COMPOUNDS
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
JP6051210B2 (ja) 2011-06-10 2016-12-27 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
US9402877B2 (en) 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2013109738A1 (en) 2012-01-17 2013-07-25 The Trustees Of Columbia University In The City Of New York Novel phosphodiesterase inhibitors and uses thereof
AR091507A1 (es) 2012-06-21 2015-02-11 Intra Cellular Therapies Inc SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
JP6549040B2 (ja) 2013-02-17 2019-07-24 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 新規使用
ES2871327T3 (es) 2013-03-15 2021-10-28 Intra Cellular Therapies Inc Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de enfermedades o trastornos de SNC o SNP
US9598426B2 (en) 2013-03-15 2017-03-21 Intra-Cellular Therapies, Inc. Organic compounds
CA2916393C (en) * 2013-06-21 2022-03-22 Intra-Cellular Therapies, Inc. Free base crystals
WO2015009930A2 (en) 2013-07-17 2015-01-22 The Trustees Of Columbia University In The City Of New York Novel phosphodiesterase inhibitors and uses thereof
AR102315A1 (es) * 2014-04-02 2017-02-22 Bayer Cropscience Ag Derivados de pirazolil-nicotin(tio)amida sustituidos y su uso como fungicidas
WO2015196186A1 (en) 2014-06-20 2015-12-23 Intra-Cellular Therapies, Inc. Organic compounds
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
EP3177627B1 (en) 2014-08-07 2019-07-24 Intra-Cellular Therapies, Inc. Imidazo[1,2-a]-pyrazolo[4,3-e]-pyrimidin-4-one derivatives with pde1 inhibiting activity
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
MX2017003646A (es) 2014-09-17 2017-07-13 Intra Cellular Therapies Inc Compuestos y metodos.
JP2019510039A (ja) 2016-03-28 2019-04-11 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 新規組成物および方法
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
ES2927104T3 (es) 2016-09-09 2022-11-02 Incyte Corp Derivados de pirazolopiridina como moduladores de HPK1 y usos de los mismos para el tratamiento del cáncer
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
EP3509589B1 (en) 2016-09-12 2021-11-17 Intra-Cellular Therapies, Inc. Novel uses
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
WO2019051199A1 (en) 2017-09-08 2019-03-14 Incyte Corporation 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS
JP7401442B2 (ja) 2018-01-31 2023-12-19 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規使用
LT3755703T (lt) 2018-02-20 2022-10-10 Incyte Corporation N-(fenil)-2-(fenil)pirimidin-4-karboksamido dariniai ir susiję junginiai, kaip hpk1 inhibitoriai, skirti vėžio gydymui
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
WO2019164847A1 (en) 2018-02-20 2019-08-29 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
US11111247B2 (en) 2018-09-25 2021-09-07 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
CR20220097A (es) 2019-08-06 2022-06-01 Incyte Corp Formas sólidas de un inhibidor de hpk1
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension
CN113493459B (zh) * 2020-04-07 2022-12-13 广州白云山医药集团股份有限公司白云山制药总厂 Pde5抑制剂化合物及其制备方法和应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2089971A (en) 1937-08-17 Condensation products of
DE425921C (de) * 1923-08-11 1926-02-27 Ernst Otto Baum Pressluftzugmaschine fuer Bergwerke
US4871843A (en) 1983-10-18 1989-10-03 Dropic-Societe Civile De Gestion De Droits De Propriete Industrielle Cyclic benzenesulfonamides, process for their preparation and their use as active substance of pharmaceutical compositions
FR2558263B1 (fr) * 1984-01-12 1986-04-25 Commissariat Energie Atomique Accelerometre directif et son procede de fabrication par microlithographie
US4663326A (en) 1985-04-04 1987-05-05 Warner-Lambert Company Pyrazolo[4,3-d]pyrimidine-5,7-(4H,6H)dione or -5-thione-7-one analogs
US4666908A (en) 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
US5075310A (en) 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
GB8817651D0 (en) 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
IL95975A (en) 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9119704D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
GB9202238D0 (en) 1992-02-03 1992-03-18 Wellcome Found Compounds
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5734053A (en) 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9213623D0 (en) 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9315017D0 (en) 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
US5728705A (en) 1993-10-04 1998-03-17 The Trustees Of Columbia University In The City Of New York Method of inducing vasorelaxation to treat pulmonary hypertension
GB9423911D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US5656629A (en) 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
KR19980702892A (ko) 1995-03-10 1998-08-05 보먼 메리 피 6-아릴 피라졸로[3,4-디]피리미딘-4-온 및 그의 조성물 및 그의사용 방법
US5952006A (en) 1995-09-29 1999-09-14 L.A.M. Pharmaceuticals, Llc Drug preparations for treating impotency
DE19540642A1 (de) 1995-11-01 1997-05-07 Stief Christian Georg Priv Doz Verwendung von Inhibitoren der Phosphodiesterase bei der Behandlung von Prostataerkrankungen
GB9612514D0 (en) 1996-06-14 1996-08-14 Pfizer Ltd Novel process
KR100390612B1 (ko) 1997-04-25 2003-07-07 화이자 인코포레이티드 타입 5 시클릭 구아노신 3',5'-모노포스페이트포스포디에스테라제를 억제하는 성기능 장애 치료용피라졸로피리미디논 제조용 중간체의 제조 방법
BR9809848A (pt) 1997-05-19 2000-06-27 Zonagen Inc Composição
CA2291256A1 (en) 1997-05-29 1998-12-03 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for erection dysfunction
ATE318602T1 (de) 1997-12-16 2006-03-15 Pfizer Prod Inc Kombination aus einem alpha-1-adrenorezeptor antagonisten und einem cgm pdev hemmer zur behandlung von impotenz
CN1134442C (zh) 1998-04-20 2004-01-14 美国辉瑞有限公司 吡唑并嘧啶酮cGMP PDE5抑制剂、其制备方法及用途及中间体
AU4068599A (en) 1998-05-20 1999-12-06 Schering Corporation Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
US6087368A (en) 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
WO2000020033A1 (fr) 1998-10-05 2000-04-13 Eisai Co., Ltd. Comprimes se delitant immediatement dans la cavite buccale
JP2000119198A (ja) 1998-10-16 2000-04-25 Eisai Co Ltd 苦味等の隠蔽されたホスフォジエステラーゼ阻害剤含有経口製剤
CA2251255A1 (en) 1998-10-20 2000-04-20 Mcgill University The use of dopaminergic agents in the management of sexual dysfunction
IL132406A0 (en) 1998-10-21 2001-03-19 Pfizer Prod Inc Treatment of bph with cgmp elevators
JP2002528456A (ja) 1998-10-23 2002-09-03 ファイザー・インク 性的機能障害の処置のためのピラゾロピリミジノン系cGMP阻害薬
GB9823101D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9828340D0 (en) 1998-12-22 1999-02-17 Novartis Ag Organic compounds
JP3199115B2 (ja) * 1998-12-24 2001-08-13 モトローラ株式会社 デジタル・アナログ変換回路
DE19903087A1 (de) 1999-01-27 2000-08-10 Forssmann Wolf Georg Behandlung von erektilen Dysfunktionen mit C-Typ Natriuretischem Polypeptid (CNP) als Monotherapie oder in Kombination mit Phosphodiesterasehemmern
CA2362918A1 (en) 1999-03-08 2000-09-14 Elizabeth Stoner Methods and compositions for treating erectile dysfunction
IL137429A0 (en) 1999-07-28 2001-07-24 Pfizer Prod Inc Methods and compsitions for treating diseases and conditions of the eye
WO2001008659A1 (en) 1999-07-30 2001-02-08 Lakefield Minerals Ltd. Pharmaceutical compositions for topical application to treat erectile dysfunction
JP2003506394A (ja) 1999-08-10 2003-02-18 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システム 視力の保持を容易にするために視神経、脈絡膜、および網膜の血流を増大させるための方法
US6436944B1 (en) 1999-09-30 2002-08-20 Pfizer Inc. Combination effective for the treatment of impotence
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
YU59100A (sh) 1999-10-11 2003-10-31 Pfizer Inc. Postupak za dobijanje pirazolo (4,3-d) pirimidin-7-ona-3-piridilsulfonil jedinjenja i njihova intermedijera
US6407259B1 (en) * 2000-07-28 2002-06-18 Pfizer Inc. Process for the preparation of pyrazoles
US6420557B1 (en) * 2000-07-28 2002-07-16 Pfizer Inc. Crystalline therapeutic agent

Also Published As

Publication number Publication date
IN2005MU00080A (es) 2006-05-19
US20100035891A1 (en) 2010-02-11
JP2003511453A (ja) 2003-03-25
AP1238A (en) 2004-01-29
EP1220856B1 (en) 2004-12-08
GEP20033142B (en) 2003-12-25
CN1572792A (zh) 2005-02-02
IN2006MU00264A (es) 2007-06-08
CN1680378A (zh) 2005-10-12
IS6320A (is) 2002-03-21
IN2007MU00567A (es) 2007-08-31
NO322856B1 (no) 2006-12-11
PH12000002783B1 (en) 2006-02-21
CU23198A3 (es) 2007-03-23
HRP20020317A2 (en) 2004-04-30
WO2001027113A3 (en) 2001-10-25
PT1220856E (pt) 2005-02-28
WO2001027113A2 (en) 2001-04-19
HK1069577A1 (en) 2005-05-27
DK1220856T3 (da) 2005-03-14
NZ518078A (en) 2003-10-31
CZ20021158A3 (cs) 2003-03-12
AU7678400A (en) 2001-04-23
GEP20033068B (en) 2003-09-25
IL149026A0 (en) 2002-11-10
ES2232502T3 (es) 2005-06-01
TR200200989T2 (tr) 2002-09-23
CN1387531A (zh) 2002-12-25
CN100378100C (zh) 2008-04-02
US6677335B1 (en) 2004-01-13
KR100549152B1 (ko) 2006-02-06
RS50476B (sr) 2010-03-02
CA2387357C (en) 2007-10-02
CA2387357A1 (en) 2001-04-19
MXPA02003627A (en) 2002-08-01
YU31402A (sh) 2005-03-15
US20040152712A1 (en) 2004-08-05
IN2002MU00385A (es) 2005-08-26
CN100383141C (zh) 2008-04-23
JP3834236B2 (ja) 2006-10-18
CR6617A (es) 2004-02-23
PL357536A1 (en) 2004-07-26
NO20021694L (no) 2002-05-27
KR20020038942A (ko) 2002-05-24
DE60016615D1 (de) 2005-01-13
PA8504501A1 (es) 2003-06-30
AU779065B2 (en) 2005-01-06
SI1220856T1 (en) 2005-06-30
DZ3220A1 (fr) 2001-04-19
HUP0203450A3 (en) 2003-05-28
AP2002002456A0 (en) 2002-06-30
SK4602002A3 (en) 2003-04-01
EA200200337A1 (ru) 2002-10-31
MA26825A1 (fr) 2004-12-20
HRP20020317B1 (en) 2007-08-31
PE20010737A1 (es) 2001-07-19
BR0014698A (pt) 2002-06-18
DE60016615T2 (de) 2005-12-22
CN1204138C (zh) 2005-06-01
EA004982B1 (ru) 2004-10-28
BG106678A (bg) 2003-01-31
CR10191A (es) 2008-10-10
HK1078574A1 (en) 2006-03-17
HUP0203450A2 (hu) 2003-01-28
EG24411A (en) 2009-05-25
ATE284404T1 (de) 2004-12-15
EE200200195A (et) 2003-08-15
NO20021694D0 (no) 2002-04-10
MY130319A (en) 2007-06-29
US7176311B2 (en) 2007-02-13
US20060293347A1 (en) 2006-12-28
TWI265925B (en) 2006-11-11
EP1220856A2 (en) 2002-07-10
TNSN00199A1 (fr) 2002-05-30
HK1050367A1 (en) 2003-06-20
IL149026A (en) 2010-05-17
IS2181B (is) 2006-12-15
SV2002000195A (es) 2002-07-16
OA12061A (en) 2006-05-03
MX228340B (en) 2005-06-07
GT200000171A (es) 2002-04-03
EE05181B1 (et) 2009-06-15

Similar Documents

Publication Publication Date Title
CO5251477A1 (es) Compuestos farmaceuticamente activos
CO5300399A1 (es) Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20021091A1 (es) Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
CO5611128A2 (es) Compuestos derivados de n-aril-2-oxazolidinona-5-carboxamida como agentes antibacteriales
TR199500981A2 (tr) Laktamlar, bilhassa azetidinilalkillaktam türevleri.
CO5251381A1 (es) Derivados de adamantano, un proceso para su preparacion y composiciones farmaceuticas que los contienen
CO6270320A2 (es) Derivados de piperidina utiles como antagonistas del receptor orexina
AR048641A1 (es) Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame
DE60015927D1 (en) Phenylharnstoff und phenylthioharnstoffderivate
AR240929A2 (es) &#34;n-piridinsulfonil-n&#39;-piridinil-y-triazinil-ureas procedimiento parasu preparacion, intermediarios para uso exclusivo en dicho procedimiento, y composiciones que contienen dichas ureas&#34;
RS49776B (sr) Fungicidni trifluormetilalkilamino- triazolpirimidini
CO4770950A1 (es) Composicion antiparasitaria para tratamiento y proteccion de animales de compania
BG97221A (bg) Ортозаместени бифениламидини и бифенилизанидини и съдържащите ги антидиабетични или хипогликемични средства
CO5261527A1 (es) Eteres del acido benzoico de oxazolidinonas que tienen un substituyente hidroxiacetilpiperazina
AR054212A1 (es) Derivados de bisarilurea sustituidos con heterociclos, composicion farmaceutica y un metodo para prepararla y compuestos intermediarios de sintesis
FI894134A0 (fi) Disubstituerade bensylaminer, deras framstaellningsprocess, deras anvaendning som medicin och deras framstaellningsaemnen.
EA200200810A1 (ru) Конденсированные соединения азола и их применение в качестве гипогликаемических агентов
PE20010300A1 (es) Preparacion de piperidin-4-onas sustituidas
CO5271679A1 (es) Inhibidores de proteasa 7-14 miembros
CO5690541A2 (es) Derivados de 1-(2,3-dihidro-1h-inden-2-il)-3-fenilurea y 1-fenil-3- (1,2,3,4-tetrahidronaftalen-2-il)urea
HU911992D0 (en) 2-(amino-alkyl)-5-(aryl-alkyl)-1,3-dioxanes, and process for the production of the medical preparations containing them
AR062113A1 (es) Derivados de eteres heterociclicos sustituidos,composiciones farmaceuticas que los contienen y usos en trastornos del cns.
ES2194709T3 (es) Procedimiento para preparar carbamatos de tetrahidrotiopiran-o-fluorados.
CO5210926A1 (es) Mezclas fungicidas
CO5251476A1 (es) Procedimiento para la preparacion de compuestos de pirazolo [4,3-d] pirimidin-7-onas-3-piridilsulfonilo e intermedios de los mismos

Legal Events

Date Code Title Description
FC Application refused